|
[Related PubMed/MEDLINE]
Total Number of Papers: 31
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2021 |
Impact of renal function on residual platelet reactivity and clinical outcomes in patients with acute coronary syndrome treated with clopidogrel. |
ACS, CKD, eGFR, MACEs |
| 2 |
2020 |
Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor. |
ACS, DAPT |
| 3 |
2020 |
Effects of morphine on P2Y12 platelet inhibitors in patients with acute myocardial infarction: A meta-analysis. |
AMI, AUC, CI, RR, RR, SMD, TIMI |
| 4 |
2020 |
Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial. |
PCI, STEMI |
| 5 |
2020 |
Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome. |
ACS, CI, CKD, eGFR, OR |
| 6 |
2019 |
Myocardial salvage after ST-segment-elevation myocardial infarction: comparison between prasugrel and clopidogrel in the presence or absence of high-residual platelet reactivity. |
MSI, PPCI, SPECT, STEMI |
| 7 |
2018 |
Body Mass Index and Plasma P-Selectin before Coronary Stenting Predict High Residual Platelet Reactivity at 6 Months on Dual Antiplatelet Therapy. |
BMI, DAPT, PCI |
| 8 |
2018 |
Platelet reactivity in patients with chronic kidney disease undergoing percutaneous coronary intervention. |
AA, ADP, CKD, mTEG, PCI |
| 9 |
2018 |
Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome. |
ACS, IST, OCT, PRU |
| 10 |
2017 |
APpropriateness Assessment in Antiplatelet THerapY (APATHY) registry: Insight from current clinical practice. |
ACS, APATHY |
| 11 |
2016 |
Aspirin resistance is associated with increased stroke severity and infarct volume. |
DWI, NIHSS |
| 12 |
2016 |
Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: The inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial. |
LD, PR |
| 13 |
2016 |
Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor. |
DAPT, PCI, SUA |
| 14 |
2016 |
Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. |
ACS, ADP, DAPT, PCIs |
| 15 |
2015 |
Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor. |
ADP, ASA, BMI, CI, DAPT, OR |
| 16 |
2015 |
High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. |
ACS |
| 17 |
2015 |
High residual platelet reactivity (HRPR) for adenosine diphosphate (ADP) stimuli is a determinant factor for long-term outcomes in acute ischemic stroke with anti-platelet agents: The meaning of HRPR after ADP might be more prominent in large atherosclerotic infarction than other subtypes of AIS. |
ADP, AIS, APAs, HRPA, LAA, OPA |
| 18 |
2015 |
Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel: results from Assessing Platelet Activity in Coronary Heart Disease (APACHE). |
APACHE, LRPR |
| 19 |
2015 |
Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor. |
ACS, ADP-antagonist, ASA, CKD, DAPT, PCI |
| 20 |
2015 |
Predictive value of high residual platelet reactivity by flow cytometry for outcomes of ischemic stroke patients on clopidogrel therapy. |
ADP, AUC, CI, OR, PAG |
| 21 |
2015 |
Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. |
CTO, LRPR, PCI |
| 22 |
2014 |
Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study. |
LTA, MACE |
| 23 |
2014 |
Switching from clopidogrel to prasugrel in patients having coronary stent implantation. |
--- |
| 24 |
2013 |
Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. |
CKD, DM, PCI |
| 25 |
2013 |
Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. |
LD, PPCI, PRU, STEMI |
| 26 |
2013 |
High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. |
--- |
| 27 |
2013 |
Pharmacodynamic effect of clopidogrel in patients undergoing transcatheter aortic valve implantation. |
--- |
| 28 |
2012 |
Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting. |
LTA, PCI, VN-P2Y12 |
| 29 |
2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. |
ACS, PCI |
| 30 |
2009 |
High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. |
DES, LRPR, ULMD |
| 31 |
2009 |
Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. |
CI, OR |
|
A Search Service for Abbreviation / Long Form
